 |
|
Is Bone Mineral Density Paradoxically Increased in Early Stage of Diabetic Nephropathy?
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Bone mineral density (BMD) is known to show a progressive loss in end-stage renal failure,1 but there have been few reports about the BMD in early stage of renal failure. We investigated the change of BMD in subjects with early stage of diabetic nephropathy. The BMDs of L2 to L4 were measured with dual-energy x-ray absorptiometry (QDR-4500; Hologic Co, Waltham, Mass), as previously reported,2-3 in 492 Japanese subjects with type 2 diabetes (206 men and 286 women, mean ± SE age, 61.7 ± 0.5 years). Early stage of nephropathy was defined as consistent proteinuria without any increase in serum creatinine level. None of the patients had received glucocorticoid, estrogen, or thiazide, which are known to influence BMD. There was no significant difference in body mass index, age, insulin dosage, or glycemic control (hemoglobin A1c) between the subjects with nephropathy (n=145) and those without (n=347). The mean ± SE BMD . . . [Full Text of this Article]Corresponding author: Hiroyuki Koshiyama, MD, PhD, Division of Endocrinology and Metabolism, Department of Internal Medicine, Hyogo Prefectural Amagasaki Hospital, Amagasaki, Hyogo 660-0828, Japan.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Hypercholesterolemia as a Possible Risk Factor for Osteopenia in Type 2 Diabetes Mellitus
Koshiyama et al.
Arch Intern Med 2001;161:1678-1678.
FULL TEXT
Lack of Positive Correlation Between Statin Use and Bone Mineral Density in Japanese Subjects With Type 2 Diabetes
Wada et al.
Arch Intern Med 2000;160:2865-2865.
FULL TEXT
Decrease in Carotid Intima-Media Thickness after 1-Year Therapy with Etidronate for Osteopenia Associated with Type 2 Diabetes
Koshiyama et al.
J. Clin. Endocrinol. Metab. 2000;85:2793-2796.
ABSTRACT
| FULL TEXT
|
